Stockscreener 앱 받기
5.06
3.23%
-0.20
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
NEOS Investment Management LLC Purchases Shares of 45,476 ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Buy" by Brokerages - MarketBeat
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Oncology Pioneer ORIC Sets Stage for 2 Major Healthcare Conference Appearances - Stock Titan
Analysts Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - Defense World
Swiss National Bank Has $504,000 Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Charles Schwab Investment Management Inc. Purchases 7,726 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC stock touches 52-week low at $6.31 amid market challenges By Investing.com - Investing.com South Africa
ORIC stock touches 52-week low at $6.31 amid market challenges - Investing.com Australia
PNC Financial Services Group Inc. Buys 2,520 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical - GlobeNewswire
Breakthrough: Novel Prostate Cancer Drug Demonstrates Powerful Two-Pronged Attack Strategy - Stock Titan
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9%Time to Sell? - MarketBeat
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance
Wedbush Reaffirms Outperform Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9% – Here’s What Happened - Defense World
(ORIC) Investment Report - news.stocktradersdaily.com
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Victory Capital Management Inc. - Defense World
Oric Pharmaceuticals Expands Equity Incentive Plan for Growth - TipRanks
(ORIC) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC's Latest Employee Stock Grants: Key Details on Compensation Package - StockTitan
Rhumbline Advisers Purchases 4,072 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
ORIC Pharmaceuticals (ORIC) Projected to Post Earnings on Monday - MarketBeat
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - Defense World
ORIC Pharmaceuticals Reports Progress in Cancer Trials - TipRanks
Wedbush Expects Increased Earnings for ORIC Pharmaceuticals - MarketBeat
ORIC Pharmaceuticals (ORIC) to Release Quarterly Earnings on Monday - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% After Analyst Upgrade - MarketBeat
(ORIC) Investment Analysis and Advice - news.stocktradersdaily.com
ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 - Defense World
ORIC Pharmaceuticals’ (ORIC) Buy Rating Reiterated at Guggenheim - Defense World
Wedbush Equities Analysts Lift Earnings Estimates for ORIC - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% on Analyst Upgrade - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 at JPMorgan Chase & Co. - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives "Buy" Rating from Guggenheim - MarketBeat
Oric Pharmaceuticals announces clinical development plans for ORIC-944, ORIC-114 - TipRanks
ORIC® Pharmaceuticals Announces Focused Registrational - GlobeNewswire
Can ORIC Pharmaceuticals' Extended Cash Runway Fuel Success in Cancer Drug Development? - StockTitan
Wedbush Reduces Earnings Estimates for ORIC Pharmaceuticals - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
2.65%
0.06%
자본화:
|
볼륨(24시간):